• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,409.98 254.36
( 0.33%)
Global Indices
Nasdaq
51,515.27 -505.40
(-0.97%)
Dow Jones
7,441.22 -91.13
(-1.21%)
Hang Seng
71,050.31 1,148.06
(1.64%)
Nikkei 225
10,505.62 11.41
(0.11%)
Forex
USD-INR
94.55 -0.09
(-0.09%)
EUR-INR
109.66 -0.13
(-0.12%)
GBP-INR
126.84 -0.25
(-0.20%)
JPY-INR
0.59 0.00
(-0.20%)

EQUITY - MARKET SCREENER

ERIS Lifesciences Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
540596
INE406M01024
230.6075957
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ERIS
76.93
19540.76
EPS(TTM)
Face Value()
Div & Yield %
18.33
1
0.51
 

Atishay secures Rs 33-lakh order from Udaipur Central Co-operative Bank
Dec 17,2025
The project is scheduled to be executed by 14 January 2026.

Atishay is primarily engaged in the business of information technology, database management, software development, e-governance, and fintech services.

On a standalone basis, the net profit of Atishay rose 26.21% to Rs 1.83 crore, while net sales rose 37.97% to Rs 17.95 crore in Q2 September 2025 over Q2 September 2024.

Shares of Atishay rose 3.07% to close at Rs 193.25 on the BSE.